ABSTRACT
Despite the development of new bone imaging modalities, scintigraphy still plays a major role in the diagnosis of a variety of bone lesions. Since its introduction in 1971, bone scintigraphy with 99mTc-labeled phosphate compounds has been one of the most sensitive noninvasive methods for diagnosis of skeletal lesions. Skeletal involvement is a frequent and severe complication of various malignancies, ultimately affecting two-thirds of all cancer patients.
